Status:
COMPLETED
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
Brief Summary
Study to evaluate treatment effect of pramipexole on RLS severity as measured by IRLS, CGI-I and RLS-6 and to evaluate the time needed to reach maintenance dose of Pramipexole (PPX)
Eligibility Criteria
Inclusion
- Patients suffering from primary RLS who are planned to be initiated on treatment with pramipexole as part of the routine care could be included into the study
- Patients not pre-treated with any dopaminergic agent (de novo patients) or patients pretreated with dopaminergic medication
- Male or female patients of any age
Exclusion
- Treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SPC) for the treatment with pramipexole
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1029 Patients enrolled
Trial Details
Trial ID
NCT02248142
Start Date
February 1 2006
Last Update
September 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.